^
4ms
Clinical • Combination therapy
|
PD-1 (Programmed cell death 1)
|
AiRuiKa (camrelizumab)
6ms
Clinical • FDA event
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
|
Keytruda (pembrolizumab)
8ms
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2) • BRCA (Breast cancer early onset) • NTRK (Neurotrophic receptor tyrosine kinase)
|
MSI-H/dMMR
1year
Clinical • Tumor Mutational Burden • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
PD-L1 expression • TMB + PD-L1 expression
1year
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Enhertu (fam-trastuzumab deruxtecan-nxki)